Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)

This study has been completed.
Information provided by:
Chugai Pharmaceutical Identifier:
First received: February 9, 2007
Last updated: January 29, 2009
Last verified: January 2009
This study will assess the efficacy and safety of intravenous R744 in renal anemia patients on hemodialysis.

Condition Intervention Phase
Hemodialysis Patients
Drug: R744
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Clinical Study of Switching From rHuEPO to R744 and Maintenance Treatment With R744 in Renal Anemia Patients on Hemodialysis (Phase Ⅲ Study)

Resource links provided by NLM:

Further study details as provided by Chugai Pharmaceutical:

Primary Outcome Measures:
  • Rate of patients who maintain Hb concentration in the range of ≥ 10.0g/dL and ≤ 12.0g/dL [ Time Frame: 48 weeks ]

Secondary Outcome Measures:
  • Slope of regression line of Hb concentration (g/dL/week) [ Time Frame: 48 weeks ]
  • Rate of patients who maintain Hb concentration in the range of baseline* ± 1.0g/dL [ Time Frame: 48 weeks ]
  • Rate of patients who maintain Hb concentration in the range of ≥ 10.0g/dL and < 13.0g/dL [ Time Frame: 48 weeks ]
  • Adverse events [ Time Frame: 48 weeks ]
  • Laboratory measurements [ Time Frame: 48 weeks ]
  • Vital signs, standard 12-lead ECG [ Time Frame: 48 weeks ]
  • Anti-R744 antibody titer [ Time Frame: 48 weeks ]

Enrollment: 179
Study Start Date: January 2007
Study Completion Date: October 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: R744
100μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
Experimental: 2 Drug: R744
150μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who have been receiving hemodialysis 3 times a week for at least 12 weeks before registration
  • Patients aged ≥ 20 years at the time of obtaining consent Patients who have been receiving a rHuEPO preparation at least once a week for at least 8 weeks before registration
  • Patients whose mean value of Hb concentrations determined before the first dialysis of each week within 8 weeks prior to the registration has been between ≥ 10.0 g/dL and <12.0 g/dL
  • Patients whose transferrin saturation has been ≥ 20 % or ferritin has been

    • 100ng/mL at any one time point within 8 weeks before registration

Exclusion Criteria:

  • Patients with hardly controllable hypertension (patients whose diastolic blood pressure has been ≥ 100 mmHg on more than 1/3 of the determining occasions within 12 weeks before registration)
  • Patients with congestive cardiac failure (≥ Class III in NYHA cardiac function classification)
  • Female patients who are pregnant, lactating, possibly pregnant or not willing to take a contraceptive measure in the period from the day of starting the treatment with the study drug to 90 days after the day of the last dose of the study drug
  • Patients with complication of myocardial infarction, pulmonary infarction or cerebral infarction (excluding asymptomatic cerebral infarction)
  • Patients confirmed to have serious allergy or serious drug allergy (shock, anaphylactoid symptom)
  • Patients hypersensitive to a rHuEPO preparation
  • Patients with malignant tumor (including hemic malignant tumor), severe infection, systemic hemic disease (osteomyelodysplasia syndrome, hemoglobinopathy, etc.), hemolytic anemia or apparent hemorrhagic lesion such as digestive tract hemorrhage
  • Patients who have received an anabolic hormone preparation, testosterone enanthate or mepitiostane within 12 weeks before registration
  • Patients who have received another investigational drug within 12 weeks before registration
  • Patients who have received R744 before registration
  • Patients whose AST(GOT) value ≥ 100 IU/L or ALT(GPT) value ≥ 100 IU/L before registration
  • Patients who have received erythrocyte transfusion within the last 16 weeks before registration
  • Patients for whom a surgical operation involved with heavy bleeding is planned during the study period
  • In addition, patients who are judged as ineligible to participate in this study by the investigator or sub-investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00433888

Chubu region
Chubu, Japan
Chugoku/Shikoku region
Chugoku/Shikoku, Japan
Hokkaido/Tohoku region
Hokkaido/Tohoku, Japan
Kanto/Koshinetsu region
Kanto/Koshinetsu, Japan
Kinki/Hokuriku region
Kinki/Hokuriku, Japan
Kyusyu region
Kyusyu, Japan
Sponsors and Collaborators
Chugai Pharmaceutical
Study Chair: Takanori Baba Clinical Research Department 2
  More Information

Responsible Party: Chugai Pharmaceutical Identifier: NCT00433888     History of Changes
Other Study ID Numbers: JH20563
Study First Received: February 9, 2007
Last Updated: January 29, 2009 processed this record on April 27, 2017